Bio-Path Holdings, Inc. (BPTH): Price and Financial Metrics


Bio-Path Holdings, Inc. (BPTH): $1.46

0.01 (+0.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BPTH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BPTH Stock Price Chart Interactive Chart >

Price chart for BPTH

BPTH Price/Volume Stats

Current price $1.46 52-week high $5.28
Prev. close $1.46 52-week low $1.28
Day low $1.46 Volume 3,900
Day high $1.48 Avg. volume 48,721
50-day MA $2.79 Dividend yield N/A
200-day MA $3.40 Market Cap 10.45M

Bio-Path Holdings, Inc. (BPTH) Company Bio


Bio-Path Holdings, Inc. focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. The company was founded in 2007 and is based in Bellaire, Texas.


BPTH Latest News Stream


Event/Time News Detail
Loading, please wait...

BPTH Latest Social Stream


Loading social stream, please wait...

View Full BPTH Social Stream

Latest BPTH News From Around the Web

Below are the latest news stories about BIO-PATH HOLDINGS INC that investors may wish to consider to help them evaluate BPTH as an investment opportunity.

H.C. Wainwright Reaffirms Their Buy Rating on Bio-Path Holdings (BPTH)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings (BPTH - Research Report) today and set a price target of $9.00. The company's shares opened today at $1.57.Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals. According to TipRanks, Chen has an average return of -28.1% and a 24.40% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Path Holdings with a $9.00 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $5.28 and a one-year low of $1.29.

Brian Anderson on TipRanks | November 15, 2022

Bio-Path Holdings Reports Third Quarter 2022 Financial Results

Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent corporate developments. “The third quarter was marked by continued progress across

Yahoo | November 15, 2022

Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022

HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, November 15, 2022 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview. To access the live con

Yahoo | November 8, 2022

Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement

HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 800,000 shares of its common stock (or common stock equivalents) for a price of $2.50 per share, for gross proceeds of

Yahoo | November 7, 2022

Bio-Path Holdings (BPTH) Receives a Buy from H.C. Wainwright

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bio-Path Holdings (BPTH - Research Report), with a price target of $9.00. The company's shares closed yesterday at $3.30.Chen covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Veru, and Belite Bio, Inc. ADR. According to TipRanks, Chen has an average return of -23.0% and a 27.12% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Path Holdings with a $9.00 average price target.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $5.

Brian Anderson on TipRanks | October 27, 2022

Read More 'BPTH' Stories Here

BPTH Price Returns

1-mo -55.89%
3-mo -61.27%
6-mo N/A
1-year -65.73%
3-year -79.86%
5-year -97.36%
YTD -61.27%
2021 7.71%
2020 -56.20%
2019 128.29%
2018 -91.25%
2017 -85.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8608 seconds.